Form 4: Director James J. Donohue Receives Acurx Stock Options
Statement of Changes in Beneficial Ownership
Acurx Pharmaceuticals director James J. Donohue was granted 2,150 stock options as part of the company's director compensation policy.
Summary
- Director James J. Donohue received a grant of 2,150 stock options on April 20, 2026.
- The options have an exercise price of $2.36 per share.
- The grant is part of the standard director compensation policy for Acurx Pharmaceuticals, Inc.
- The options are scheduled to vest on April 20, 2027, and expire on April 20, 2036.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative disclosure regarding director compensation with no material impact on the company's financial outlook.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
Negatives
- Minor dilution of existing shareholders upon the eventual exercise of these options.
Risks
- The value of the options is dependent on the future market performance of ACXP common stock.
Future Outlook
The filing does not provide forward-looking financial guidance, focusing solely on the disclosure of director equity compensation.
Management Comments
- The stock option award is related to service on the Issuer's board of directors granted pursuant to the Issuer's Director Compensation Policy.
Industry Context
StockSavvy.ai notes that equity-based compensation for board members is a standard corporate governance practice in the biotechnology sector to ensure directors remain incentivized to oversee long-term strategic growth.
Comparison to Industry Standards
- The grant of stock options to non-executive directors is consistent with standard compensation practices for small-cap pharmaceutical companies.
- The vesting period of one year is typical for director equity awards in the industry.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Director Compensation | Grant of stock options to Director James J. Donohue. | 04/20/2026 | Standard alignment of director incentives. |
Stakeholder Impact
- Minimal impact on shareholders due to the small size of the option grant.
Next Steps
- Vesting of the granted options on April 20, 2027.
Key Dates
| Date | Description |
|---|---|
| 04/20/2026 | Date of grant for the stock options. |
| 04/20/2027 | Vesting date for the stock options. |
| 04/20/2036 | Expiration date for the stock options. |
Keywords
Acurx Pharmaceuticals, ACXP, Form 4, Insider Trading, Director Compensation, Stock Options
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.